ReviewDrug safety2015

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Rashmi R Shah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.